Triple protection of SGLT2i: ACT2DAY for patients’ future

Chairs: John Wilding (GBR), Xavier Cos (ESP)

17:00 – 17:02IntroductionJohn Wilding (GBR)
17:02 – 17:10Early glycemic control with SGLT2 inhibitors and its long-lasting benefitsJohn Wilding (GBR)
17:10 – 17:18Blunting the progression of kidney disease with Canagliflozin in patients with T2D: How, when and who?Hiddo L. Heerspink (NLD)
17:18 – 17:26Getting to the heart of the matter: Canagliflozin cardiovascular benefits in T2DDavid Matthews (GBR)
17:26 – 17:34Cardio-renal-metabolic care in T2D: be holistic!Apostolos Tsapas (GRC)*
17:34 – 17:38Round table introductionXavier Cos (ESP)
17:38 – 17:58Round table: addressing barriers for early initiation of the therapyAll faculty
17:58 – 18:00Wrap-up and takeaway messagesJohn Wilding (GBR)

*Independent comment and pro-bono participation